Sugi Predict

Sugi Predict / Compounds / SCHEMBL6888403

SCHEMBL6888403

SCHEMBL6888403

CC(C)(C)OC(=O)NC1(C(=O)O)CC(F)(F)C1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ APLNR P35414 1/20 0.35
▸ BTK Q06187 1/20 0.33
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ CA7 P43166 1/20 0.33
▸ CTSL P07711 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ CTSS P25774 1/20 0.32
▸ CTSK P43235 1/20 0.32
▸ LPAR1 Q92633 2/20 0.32
▸ GHSR Q92847 1/20 0.31
▸ NFKB1 P19838 1/20 0.31
▸ NFKB2 Q00653 1/20 0.31
▸ RELA Q04206 1/20 0.31
▸ CA12 O43570 1/20 0.31
▸ CA14 Q9ULX7 1/20 0.31
▸ TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22749349 0.89 MEN1 (0.33) KMT2AMEN1MAPK1APLNRBTK
SCHEMBL22363074 0.89 MEN1 (0.33) KMT2AMEN1MAPK1APLNRBTK
SCHEMBL22362839 0.85 MEN1 (0.35) KMT2AMEN1MAPK1APLNRCA1
SCHEMBL19920575 0.85 KMT2A (0.35) KMT2AMEN1MAPK1APLNRCA1
SCHEMBL15114559 0.85 TSHR (0.35) KMT2AMEN1MAPK1APLNRBTK
SCHEMBL17605642 0.83 MEN1 (0.34) KMT2AMEN1MAPK1APLNRCA1
SCHEMBL19920518 0.83 SLC10A1 (0.35) KMT2AMEN1MAPK1APLNRCA1
SCHEMBL22380393 0.82 MEN1 (0.33) KMT2AMEN1MAPK1APLNRCA1
SCHEMBL142219 0.82 MEN1 (0.39) KMT2AMEN1MAPK1APLNRBTK
SCHEMBL5103879 0.80 BTK (0.35) KMT2AMEN1MAPK1APLNRBTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260069602-A1 COMPOUNDS, COMPOSITIONS, AND METHODS ACONCAGUA BIO INC (US) 2026-03-12 — — US disclosed
US-20260028341-A1 IMIDAZOTRIAZINE DERIVATIVES AS IL-17 MODULATORS UCB Biopharma SRL (BE) 2026-01-29 — — US disclosed
US-20250304554-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF GILEAD SCIENCES, INC. 2025-10-02 — — US disclosed
EP-4558223-A1 IMIDAZOTRIAZINE DERIVATIVES AS IL-17 MODULATORS UCB Biopharma SRL (BE) 2025-05-28 — — EP disclosed
CN-119823001-A Urea compounds antagonizing LPA1 receptor 大正制药株式会社 2025-04-15 — — CN disclosed
CN-114206832-B Urea compounds antagonizing LPA1 receptor 大正制药株式会社 2025-04-04 — — CN disclosed
US-12161625-B2 Substituted pyrrolizine compounds and uses thereof GILEAD SCIENCES, INC. (US) 2024-12-10 — — US disclosed
US-12116356-B2 N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2024-10-15 — — US disclosed
US-11912686-B2 LPA receptor antagonists and uses thereof GILEAD SCIENCES, INC. (US) 2024-02-27 — — US disclosed
US-11912686-B2 LPA receptor antagonists and uses thereof GILEAD SCIENCES, INC. (US) 2024-02-27 — — US disclosed
WO-2018039531-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2018-03-01 — — WO disclosed
US-9199981-B2 Compounds and compositions as C-kit kinase inhibitors NOVARTIS AG (CH) 2015-12-01 — — US disclosed
US-9199981-B2 Compounds and compositions as C-kit kinase inhibitors NOVARTIS AG (CH) 2015-12-01 — — US disclosed
US-9199981-B2 Compounds and compositions as C-kit kinase inhibitors NOVARTIS AG (CH) 2015-12-01 — — US disclosed
EP-2751102-A1 COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS IRM LLC (BM) 2014-07-09 — — EP disclosed
WO-2013033070-A1 COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS IRM LLC (BM) 2013-03-07 — — WO disclosed
US-20130059846-A1 COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS IRM LLC (BM) 2013-03-07 — — US disclosed
US-20130059846-A1 COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS IRM LLC (BM) 2013-03-07 — — US disclosed
WO-2011070539-A1 CYSTEINE PROTEASE INHIBITORS MEDIVIR UK LIMITED (GB) 2011-06-16 — — WO disclosed
WO-2011070541-A1 CYSTEINE PROTEASE INHIBITORS MEDIVIR UK LIMITED (GB) 2011-06-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12161625-B2 Substituted pyrrolizine compounds and uses thereof HMBS, DHFR, HCCS KMT2A 2946/4885MEN1 3929/4885MAPK1 3270/4885
US-20260028341-A1 IMIDAZOTRIAZINE DERIVATIVES AS IL-17 MODULATORS IL17A, IL6ST, IL6 KMT2A 2415/4885MEN1 4148/4885MAPK1 435/4885
US-12116356-B2 N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof COG5, HAVCR2, ZC3HAV1 KMT2A 4197/4885MEN1 3004/4885MAPK1 2209/4885
US-20130059846-A1 COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS KIT, PDGFRA, PDGFRB KMT2A 792/4885MEN1 2180/4885MAPK1 245/4885
US-20260069602-A1 COMPOUNDS, COMPOSITIONS, AND METHODS SCTR, SSTR1, NPY1R KMT2A 4817/4885MEN1 465/4885MAPK1 2195/4885
US-20250304554-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF LPAR1, LPAR2, LPAR4 KMT2A 1686/4885MEN1 4723/4885MAPK1 1397/4885
US-11912686-B2 LPA receptor antagonists and uses thereof LPAR1, LPAR2, LPAR4 KMT2A 1686/4885MEN1 4723/4885MAPK1 1397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.